RESEARCH PAPER
Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries
Patricia de los Rios 1  
,   Chinyere Okoli 2  
,   Benjamin Young 1  
,   Brent Allan 3  
,   Erika Castellanos 4  
,   Garry Brough 5  
,   Anton Eremin 6  
,   Giulio M. Corbelli 7  
,   W. David Hardy 8  
,   Nicolas Van de Velde 2  
 
More details
Hide details
1
ViiV Healthcare, Research Triangle Park, United States
2
ViiV Healthcare, Brentford Middlesex, United Kingdom
3
International Council of AIDS Service Organizations (ICASO), Toronto, Canada
4
Global Action for Trans* Equality (GATE)
5
Positively UK, London, United Kingdom
6
AIDS Center Foundation, Moscow, Russia
7
European AIDS Treatment Group, Rome, Italy
8
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, United States
CORRESPONDING AUTHOR
Patricia de los Rios   

ViiV Healthcare, Research Triangle Park, North Carolina, 27709, United States
Submission date: 2020-05-09
Final revision date: 2020-06-28
Acceptance date: 2020-06-29
Publication date: 2020-07-31
 
Popul. Med. 2020;2(July):23
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The worldview in relation to patient care has shifted from conquering diseases to improving overall wellbeing and quality of life. We examined treatment aspirations among people living with HIV (PLHIV).

Methods:
In all, 2389 PLHIV were surveyed in the 25-country 2019 Positive Perspectives Study. Descriptive and multivariable analyses were used to explore attitudes towards treatment.

Results:
Participants were from: Northern America (USA, Canada), 21.8% (520/2389); Europe, 46.8% (1119/2389); and other international regions, 31.4% (750/2389). Factors associated with some level of dissatisfaction with HIV medication among those otherwise fully satisfied with their HIV management included being on a multi-tablet regimen (AOR=2.76; 95% CI: 1.93–3.96), reporting polypharmacy (AOR=2.10; 95% CI: 1.45–3.03), and experiencing side effects from current HIV medication (AOR=2.12; 95% CI: 1.49–3.02). Of seven improvements to HIV medications assessed, the percentage ranking each attribute, as the first or second most important, was: ‘reduced long-term impact on my body’ (46.7%); ‘longer-lasting medicine so I don’t have to take it every day’ (43.1%); ‘fewer side effects’ (40.5%); ‘less HIV medicine each day but just as effective’ (25.4%); ‘less chance of affecting other medicines’ (21.6%); ‘no food restrictions/ requirements’ (14.0%); and ‘smaller pills’ (8.7%). Overall, 77.1% (1842/2389) believed ‘future advances in HIV treatment will improve my overall wellbeing’, 72.2% (1726/2389) were ‘open to taking an HIV treatment composed of fewer medicines’, while 54.7% (1306/2389) expressed openness towards longer-acting (non-daily) HIV medication. Compared to those not fully satisfied with either their HIV medication or management, those fully satisfied with both reported significantly higher prevalence of optimal treatment adherence (89.2% [372/417] vs 69.5% [763/1098]) and optimal overall health (70.3% [293/417] vs 47.8% [525/1098]) (all p<0.001).

Conclusions:
Many PLHIV perceived gaps in their care and aspired for novel treatments. Providing flexible treatment options can help patients across the spectrum of unmet needs and improve health-related quality of life.

ACKNOWLEDGEMENTS
Statistical analyses and medical services were provided by Zatum LLC.
CONFLICTS OF INTEREST
The authors have each completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. E. Castellanos and B. Allan report personal fees from ViiV Healthcare during the conduct of the study, and personal fees from ViiV Healthcare outside the submitted work. N. Van de Velde reports other grants from ViiV Healthcare and GlaxoSmithKline outside the submitted work. G. M. Corbelli reports personal fees from ViiV Healthcare during the conduct of the study, and personal fees from ViiV Healthcare and HIV Vaccine Trials Network outside the submitted work. W.D. Hardy reports personal fees from ViiV Healthcare, during the conduct of the study; personal fees from ViiV Healthcare, personal fees from Advisory Boards, personal fees from Merck, personal fees from Gilead Sciences, outside the submitted work. P. de los Rios and B. Young report other grants from ViiV Healthcare during the conduct of the study, as well as outside the submitted work. A. Eremin and C. Okoli report personal fees from ViiV Healthcare, during the conduct of the study. P. de los Rios, C. Okoli, B. Young, and N. Van de Velde are employees of ViiV Healthcare.
FUNDING
This work was supported by ViiV Healthcare.
AUTHORS' CONTRIBUTIONS
PD, CO, BY and NV conceptualized the study. All authors contributed to study design, analyses, drafting of the manuscript, and substantial revisions. All authors gave final approval for the manuscript to be submitted.
PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.
 
REFERENCES (32)
1.
Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167-174. doi:10.2174/187152611795589663
 
2.
Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84. doi:10.1097/01.qai.0000225015.43266.46
 
3.
U.S. Department of Health and Human Services, Health Resources and Services Administration, Guide for HIV/AIDS Clinical Care – 2014 Edition. Rockville, MD: U.S. Department of Health and Human Services; 2014. Available at https://hab.hrsa.gov/sites/def.... Accessed March 20, 2020.
 
4.
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72. doi:10.1136/bmj.312.7023.71
 
5.
Lyu H, Xu T, Brotman D, et al. Overtreatment in the United States. PLoS ONE. 2017;12(9):e0181970. doi:10.1371/journal.pone.0181970
 
6.
St Clair-Sullivan N, Mwamba C, Whetham J, Bolton Moore C, Darking M, Vera J. Barriers to HIV care and adherence for young people living with HIV in Zambia and mHealth. Mhealth. 2019;5:45. doi:10.21037/mhealth.2019.09.02
 
7.
Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful hiv treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831. doi:10.3389/fphar.2017.00831
 
8.
Haberer JE, Sabin L, Amico KR, et al. Improving antiretroviral therapy adherence in resource‐limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017;20(1):21371. doi:10.7448/IAS.20.1.21371
 
9.
Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC Public Health. 2018;18(1):825. doi:10.1186/s12889-018-5731-z
 
10.
Holtzman CW, Brady KA, Yehia BR. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs. 2015;75(5):445-454. doi:10.1007/s40265-015-0373-2
 
11.
Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003;11(6):185-198. PMID:14724327.
 
12.
Bukenya D, Mayanja BN, Nakamanya S, Muhumuza R, Seeley J. What causes non-adherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda. AIDS Res Ther. 2019;16(1):2. doi:10.1186/s12981-018-0214-y
 
13.
Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124-133. doi:10.1037/0278-6133.19.2.124
 
14.
Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499-1510. doi:10.1016/S0140-6736(17)31917-7
 
15.
Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145-1155. doi:10.1016/S1473-3099(15)00152-8
 
16.
Joint United Nations. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Unaids; 2014. https://www.unaids.org/sites/d.... Accessed June 20, 2020.
 
17.
Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV–the new quality of life frontier. BMC Medicine. 2016;14(1):94. doi:10.1186/s12916-016-0640-4
 
18.
Mahy M, Autenrieth CS, Stanecki K, Wynd S. Increasing trends in HIV prevalence among people aged 50 years and older: evidence from estimates and survey data. AIDS. 2014;28(4):S453-S459. doi:10.1097/qad.0000000000000479
 
19.
UNAIDS. HIV and Aging: A special supplement to the UNAIDS report on the global AIDS epidemic 2013. https://reliefweb.int/sites/re.... Accessed June 20, 2020.
 
20.
Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-536. doi:10.1097/QAI.0b013e31819675e9
 
21.
Barr L, Jefferys R. A landscape analysis of HIV cure-related clinical trials and observational studies in 2018. J Virus Erad. 2019;5(4):212-219. doi:10.1016/s2055-6640(20)30030-3
 
22.
Moore DA, Goodall RL, Ives NJ, Hooker M, Gazzard BG, Easterbrook PJ. How generalizable are the results of large randomized controlled trials of antiretroviral therapy?. HIV Med. 2000;1(3):149-154. doi:10.1046/j.1468-1293.2000.00019
 
23.
Gwadz MV, Colon P, Ritchie AS, et al. Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials. Curr HIV/AIDS Rep. 2010;7(4):194-200. doi:10.1007/s11904-010-0055-3
 
24.
U.S. Food and Drug Administration. FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment. https://www.fda.gov/news-event.... Published April 8, 2019. Accessed February 12, 2020.
 
25.
Hideo A, James F. An R package and tutorial for case 2 best–worst scaling. Journal of Choice Modelling. 2019;32:100171. doi:10.1016/j.jocm.2019.100171
 
26.
DisplayR. MaxDiff Analysis Case Study Using R. https://docs.displayr.com/wiki.... Accessed April 10, 2020.
 
27.
de los Rios P, Okoli C, Punekar Y, et al. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Prev Med. 2020;139:106182. doi:10.1016/j.ypmed.2020.106182
 
28.
Sirur R, Richardson J, Wishart L, Hanna S. The role of theory in increasing adherence to prescribed practice. Physiother Can. 2009;61(2):68-77. doi:10.3138/physio.61.2.68
 
29.
Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS. 2005;19(1):9-18. doi:10.1089/apc.2005.19.9
 
30.
Delestras S, Roustit M, Mazet R, et al. Patient satisfaction with medication as an outcome for clinical pharmacists. International Journal of Clinical Pharmacy. 2005;19(1):9-18.
 
31.
Ventura Cerda JM, Martin Conde MT, Morillo Verdugo R, Tebenes Cortes M, Casado Gomez MA. [Adherence, satisfaction and health-related quality of life in HIV-infected patients with antiretroviral therapy in Spain. The ARPAS study]. Farmacia Hospitalaria. 2014;38(4):291-299.
 
32.
Boretzki J, Wolf E, Wiese C, et al. Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study. Patient Prefer Adherence. 2017;11:1897-1906. doi:10.2147/ppa.s141762
 
ISSN:2654-1459